Copenhagen, June 24, 2026, 14:21 CEST
- Ambu traded down 9.4% to 56.75 DKK on the Copenhagen exchange.
- Danske Bank downgraded the shares to “sell” from “hold” and dropped its price target to 58 DKK.
- The bank pointed to faster pricing and competition pressure in urology, where Ambu sells single-use scopes.
Ambu A/S dropped over 9% Wednesday as Danske Bank lowered its rating on the medical device group to “sell” from “hold.” The move comes with the stock still near multi-year lows. Shares were at 56.75 DKK at 1359 GMT+2, off 9.4% for the session, after hitting 56.25 DKK. Google
The action took place in normal trading hours on Nasdaq Copenhagen. The bourse runs from 0900 to 1700 local time on weekdays. June 24 doesn’t appear on the 2026 Copenhagen market holiday schedule. Trading Hours
Danske Bank lowered its price target for Ambu to 58 DKK from 70 DKK, MarketWire reported via Sydinvest. Analyst Tobias Berg Nissen set the lowest target out of nine firms tracked by Bloomberg News, according to the report.
Danske Bank cut its view on Ambu, saying growth at the company has slowed as rivals in urology moved in more quickly than expected. Ambu sells single-use endoscopes in the urology space, disposable scopes used for one procedure. The bank’s note flagged weak sales for Ambu’s ureteroscope, which is used in kidney and urinary tract work.
Danske flagged Ambu’s product mix as a concern. The bank said Ambu’s smaller range makes it harder to bundle gear versus Boston Scientific and Dornier Medtech. Ambu is getting squeezed by bigger players and cheaper rivals, Danske said.
Ambu said it bought 314,237 shares between June 15 and June 19 as part of its ongoing buyback plan. Total shares bought now stand at 1.62 million, costing 103.0 million DKK. The company said it still has 197.0 million DKK left to spend under the program.
Ambu started its buyback after the company’s May 6 half-year report. The company posted a 7.3% organic revenue rise in the second quarter, stripping out currency and acquisitions. Endoscopy Solutions jumped 13.8%, but Anesthesia & Patient Monitoring dropped 2.5%.
Ambu CEO Britt Meelby Jensen said Endoscopy Solutions turned in a “solid” quarter, but called performance in “Anesthesia & Patient Monitoring” “weaker than expected”. Ambu tightened its full-year organic revenue view to 10%-12%, down from the prior 10%-13% range. EBIT margin guidance before special items stays at 12%-14%. Via Ritzau
But there’s risk both ways. If urology price pressure and weak U.S. contract volumes stick around, analysts could lower estimates again. Still, if endoscopy keeps growing and the buyback keeps taking in shares, the drop could look overdone. The next check comes with Ambu’s third-quarter earnings on Aug. 26.
